Publication | Closed Access

Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells

Toll-like ReceptorsTlr3–irf3 SignalingInnate Immune SystemImmunologyTumor ImmunityTherapeutic VaccineToll-like Receptor 3T Cell ImmunityCd4 T Cell ResponsesImmunotherapeuticsInnate ImmunityDendritic Cell BiologyImmunotherapyMedicineCell BiologyViral ImmunityDendritic Cells